Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

BACKGROUND: FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFORT study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Satake, Hironaga, Ando, Koji, Oki, Eiji, Shimokawa, Mototsugu, Makiyama, Akitaka, Saeki, Hiroshi, Tsuji, Akihito, Mori, Masaki
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Study Protocol
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7672899/
https://ncbi.nlm.nih.gov/pubmed/33203393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07576-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky